PURPOSE: To provide an arterialization inhibitor having a remarkable arterialization-inhibiting activity and useful for preventing and treating diabetic retinopathy, etc., caused by the abnormal multiplication of blood vessels by containing a spirooctane compound.
CONSTITUTION: An arterialization inhibitor contains at least one kind of spirooctane compounds of formula I, II and III and salts thereof. The active ingredient can be mixed with a carrier acceptable as a medicine and orally or parenterally administrated to mammal animals including human being in a preparation shape such as capsules, tablets, granules or powder. The carrier includes an excipient such as scrose or starch, a binder such as cellulose or methylcellulose and a disintegrating agent such as starch. The preferable dose of the compound is usually 0.01-10mg/kg/day on injection administration and 0.5-50mg/kg/day on oral administration.
OTSUKA TAKANAO
MORIKAWA NORIYUKI
TERANO HIROSHI
OKUHARA MASAKUNI
Next Patent: ENDONASAL PHARMACEUTICALS BASED ON PHYSOSTIGMINE AND ARECOLINE